Prostate cancer screening breakthrough could prevent overdiagnoses by up to half

Written by Jolie Neill (Future Science Group)

prostate cancer screening

A breakthrough study conducted by researchers at the Karolinska Institutet of Solna in Sweden, published in the New England Journal of Medicine, examines a promising new diagnostic pathway for prostate cancer. The study demonstrates that overdiagnoses of low-risk cancers, one of the major barriers to nationwide screening, could be halved by this novel diagnostic pathway. At present, prostate-specific antigen (PSA) tests and traditional biopsies are the primary tools for diagnosing prostate cancer despite a lack of specificity and frequent overdiagnosis of low-risk cancers. However, the randomized STHLM3MRI study of 12,750 Swedish men, conducted between 2018–2021, has shown promise for increasing...

To view this content, please register now for access

It's completely free